Semaglutide 5mg (GLP-1 S)
GLP-1 receptor agonist — clinically proven weight loss and metabolic health.
14.9%
Avg body weight reduction
68wk
STEP-1 trial duration
FDA
Reviewed mechanism
Semaglutide is a GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and drives clinically significant weight loss of 10–15% body weight in 68-week trials.
14.9% Weight Loss
Average body weight reduction in STEP 1 trial — 14.9% vs 2.4% placebo over 68 weeks.
Starter Dose
5mg vial provides a starter supply for the dose-escalation protocol commonly used in clinical settings.
Multi-Organ Action
Acts on brain, gut, pancreas, and adipose simultaneously — comprehensive metabolic intervention.
Semaglutide (GLP-1 S) 5mg: The Research Protocol Guide
Mechanism · Evidence · Application
Semaglutide is a GLP-1 (Glucagon-Like Peptide-1) receptor agonist — a class of peptide that mimics the body's natural GLP-1 hormone, which is released from the gut after eating. GLP-1 is a powerful regulator of appetite, gastric emptying, and insulin secretion. Semaglutide has 94% structural homology to human GLP-1 but with modifications that extend its half-life to approximately 7 days, enabling once-weekly dosing.
Why GLP-1 Agonists Work
GLP-1 receptors are expressed in the brain (hypothalamus, brainstem), pancreas, gut, heart, and adipose tissue. Semaglutide acts on all of these simultaneously:
- **Brain**: Reduces appetite by acting on hypothalamic satiety centers
- **Gut**: Slows gastric emptying, increasing satiety duration
- **Pancreas**: Stimulates insulin secretion in response to glucose (glucose-dependent)
- **Adipose**: Promotes fat oxidation and reduces lipogenesis
The Clinical Evidence
The STEP clinical trials with semaglutide are among the most impactful in metabolic medicine: - STEP 1: 14.9% average body weight reduction over 68 weeks (vs. 2.4% placebo) - 33% of participants lost more than 20% of body weight - Improvements in blood pressure, lipids, and glycemic control
Quality Assurance
Apollo Peptides Sciences GLP-1 S is pharmaceutical-grade semaglutide with HPLC purity verification and a Certificate of Analysis available for every batch.
Metabolic & Weight Loss Results
10–15% average body weight reduction in 68-week clinical trials
Reduces appetite via hypothalamic GLP-1 receptor activation
Slows gastric emptying — extends satiety for hours post-meal
Glucose-dependent insulin stimulation — metabolically safe profile
Improves cardiovascular risk markers (blood pressure, LDL, triglycerides)
Once-weekly dosing due to 7-day half-life
Reduces liver fat (non-alcoholic fatty liver disease improvement)
Preserves lean muscle mass relative to total weight lost
Weight Loss Protocol Guide
Semaglutide 5mg (GLP-1 S) Protocol Guide
Standard Research Escalation Protocol:
· Week 1–4: 0.25mg once weekly subcutaneous
· Week 5–8: 0.5mg once weekly
· Week 9–12: 1.0mg once weekly
· Week 13+: 1.7–2.4mg once weekly (if well tolerated)
Injection Timing:
· Once weekly subcutaneous injection (abdomen, thigh, or upper arm)
· Same day each week for consistency
· No fasting required
Common Side Effects (Dose-Dependent):
· Nausea most common during dose escalation — typically resolves with time
· Slow escalation protocol minimizes gastrointestinal effects
Semaglutide 5mg (GLP-1 S)
Apollo Peptides Sciences
$79.99
Buy from ApolloAffiliate link · supports PeptidesClav
Body Composition
GLP-1 receptor agonist — clinically proven weight loss and metabolic health.
Quality Assurance
HPLC Testing
Purity verified per batch
Mass Spectrometry
Molecular identity confirmed
Certificate of Analysis
Publicly available
US-Based Supplier
Apollo Peptides Sciences
Synergistic Combinations
Stack Semaglutide 5mg (GLP-1 S) With
Ready to Start?
Begin your Semaglutide 5mg (GLP-1 S) protocol
Source from Apollo Peptides Sciences — HPLC-tested, mass-spectrometry verified, with a Certificate of Analysis per batch.
Shop Semaglutide 5mg (GLP-1 S) at Apollo